Elicio Therapeutics, Inc. (ANGN) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	S-1/A
Revenues [+]	2.3	28.3	2.9	1.5	4.0
Royalties			39.0	29.8	12.6
Net interest income	0.8	-1.8
Revenue growth	-91.9%	883.1%	93.7%	-63.1%
Cost of goods sold	0.0	0.4	0.0	0.0	18.4
Gross profit	2.3	27.9	2.9	1.5	-14.3
Gross margin	100.0%	98.5%	100.0%	100.0%	-356.0%
Selling, general and administrative [+]	14.6	18.5	18.0	9.6	5.4
General and administrative	14.6	18.5	18.0	9.6	5.4
Research and development	18.1	48.7
Equity in earnings					0.1
Other operating expenses			40.2	30.5	-5.4
EBITDA [+]	-30.3	-39.2	-55.2	-38.5	-14.2
EBITDA growth	-22.8%	-29.0%	43.3%	171.6%
EBITDA margin	-1315.0%	-138.5%	-1917.8%	-2591.9%	-352.2%
Depreciation and amortization	0.2	0.1	0.1	0.1	0.0
EBIT [+]	-30.4	-39.3	-55.3	-38.6	-14.2
EBIT growth	-22.6%	-29.0%	43.4%	171.9%
EBIT margin	-1322.7%	-138.8%	-1921.2%	-2595.2%	-352.3%
Non-recurring items [+]	9.2		-0.1
Asset impairment	9.2
Loss (gain) on sale of assets			-0.1
Interest expense, net [+]			8.8	-0.3
Interest expense			8.8
Interest income				0.3
Other income (expense), net [+]	0.8	-15.3	-16.0	-2.3	-5.8
Gain (loss) on debt retirement		0.9
Gain (loss) on foreign currency transactions	-0.2	-0.2
Change in fair value of warrants	0.1	-2.9
Pre-tax income	-38.8	-54.6	-80.1	-40.7	-20.0
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate		0.0%	0.0%	0.0%	0.0%
Net income	-38.8	-54.6	-80.1	-40.7	0.0
Net margin	-1686.5%	-192.8%	-2781.5%	-2734.2%	-0.6%

Basic EPS [+]	($1.29)	($1.93)	($5.43)	($2.82)	($2.58)
Growth	-33.1%	-64.4%	92.7%	9.1%
Diluted EPS [+]	($1.29)	($1.93)	($5.43)	($2.82)	($2.58)
Growth	-33.1%	-64.4%	92.7%	9.1%

Shares outstanding (basic) [+]	30.0	28.2	14.8	14.4	0.0
Growth	6.4%	91.3%	2.3%	148934.1%
Shares outstanding (diluted) [+]	30.0	28.2	14.8	14.4	0.0
Growth	6.4%	91.3%	2.3%	148934.1%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.